ConductScience.org, home

Paper41892443

Revisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies.

Montini VH and 9 others. Antibiotics (Basel), 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Revisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies. Papers, record 41892443. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41892443

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Revisiting the Fight Against Acinetobacter baumannii: Emerging Non-Antibiotic Strategies.
PubMed
Journal
Antibiotics (Basel)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-08-13
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Montini VHVictor Hugohttps://orcid.org/0000-0003-1033-3442
2Buso LSLaura Santanahttps://orcid.org/0009-0002-1015-9616
3Takata PHPedro Henriquehttps://orcid.org/0009-0008-4597-8498
4Santos GHMGabriel Henrique Maximino
5Gonçalves BCBruna Carolinahttps://orcid.org/0000-0002-9958-9112
6Endo THThiago Hideohttps://orcid.org/0000-0002-3830-0426
7Santos MHMMariana Homem de Mellohttps://orcid.org/0000-0001-7145-709X
8Vespero ECEliana Carolina
9Kobayashi RKTRenata Katsuko Takayamahttps://orcid.org/0000-0001-7170-2155
10Nakazato GGerson

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
01.22.0200-00FINEP - Materiais Avançados (161/21)PubMed

Source PubMed

Download CSV of grants

References103

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138719540Lactate metabolism promotes in vivo fitness during Acinetobacter baumannii infection.FEMS Microbiol Lett2024https://conductscience.org/library/papers/38719540PubMed
238797178Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.Lancet2024https://conductscience.org/library/papers/38797178PubMed
333969154Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model.Virusdisease2021https://conductscience.org/library/papers/33969154PubMed
439061334The Many Lives of Auranofin: How an Old Anti-Rheumatic Agent May Become a Promising Antimicrobial Drug.Antibiotics (Basel)2024https://conductscience.org/library/papers/39061334PubMed
535402883A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.iScience2022https://conductscience.org/library/papers/35402883PubMed
638743467Resistance to bacteriophage incurs a cost to virulence in drug-resistant Acinetobacter baumannii.J Med Microbiol2024https://conductscience.org/library/papers/38743467PubMed
739421030In silico approaches supporting drug repurposing for Leishmaniasis: a scoping review.EXCLI J2024https://conductscience.org/library/papers/39421030PubMed
837113664A fresh pH-responsive imipenem-loaded nanocarrier against Acinetobacter baumannii with a synergetic effect.Front Bioeng Biotechnol2023https://conductscience.org/library/papers/37113664PubMed
940582411Isolation and identification of a newly discovered broad-spectrum Acinetobacter baumannii phage and therapeutic validation against pan-resistant Acinetobacter baumannii.Virol Sin2025https://conductscience.org/library/papers/40582411PubMed
1038517956Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics against Acinetobacter baumanni.Sci Adv2024https://conductscience.org/library/papers/38517956PubMed
1136340146Drug-Repurposing Approach To Combat Staphylococcus aureus: Biomolecular and Binding Interaction Study.ACS Omega2022https://conductscience.org/library/papers/36340146PubMed
1237855599Acinetobacter baumannii coordinates central metabolism, plasmid dissemination, and virulence by sensing nutrient availability.mBio2023https://conductscience.org/library/papers/37855599PubMed
1333718279Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease.Front Cell Infect Microbiol2021https://conductscience.org/library/papers/33718279PubMed
1435378227Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria.Int J Antimicrob Agents2022https://conductscience.org/library/papers/35378227PubMed
1523892192Nanotechnology as a therapeutic tool to combat microbial resistance.Adv Drug Deliv Rev2013https://conductscience.org/library/papers/23892192PubMed
1641367424Identification of multi-drug resistant Acinetobacter baumannii phage YZ2 and evaluation of its therapeutic efficacy in vivo and in vitro.Front Microbiol2025https://conductscience.org/library/papers/41367424PubMed
1734031472Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii.Sci Rep2021https://conductscience.org/library/papers/34031472PubMed
1840341530Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.Sci Rep2025https://conductscience.org/library/papers/40341530PubMed
1939415253Antibacterial and wound healing potential of biosynthesized zinc oxide nanoparticles against carbapenem-resistant Acinetobacter baumannii: an in vitro and in vivo study.Microb Cell Fact2024https://conductscience.org/library/papers/39415253PubMed
2037268109The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms.J Microbiol Methods2023https://conductscience.org/library/papers/37268109PubMed

See all 103 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42756188Pre-treatment serum extracellular vesicle-enriched microbiome profiles and SSRI treatment response in obsessive-compulsive disorder: a prospective naturalistic cohort study.Front Psychiatry2026https://conductscience.org/library/papers/42756188PubMed
42423746Silver-based N-heterocyclic carbene (NHC) complexes as emerging strategies against antimicrobial resistance.Arch Microbiol2026https://conductscience.org/library/papers/42423746PubMed
42357332Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-Resistant Acinetobacter baumannii: Toward Precision Antimicrobial Intervention.Pharmaceutics2026https://conductscience.org/library/papers/42357332PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41892443

GET https://conductscience.org/api/papers/v1/41892443/references?page=2